Skip to content

Pharmacogenetic-Guided Antidepressant Prescribing in Adolescents With Anxiety and Depression

Anxiety and Depression

This is a parallel arm randomized (1:1) controlled trial. Adolescents aged 12-17 years (n=452) who are starting or changing a selective serotonin reuptake inhibitor (SSRI) for depression and/or anxiety will be randomly allocated to receive 12-weeks of pharmacogenetic-guided antidepressant therapy (experimental intervention) or current prescribing guidelines/recommendations guided therapy (control intervention).

null

Conditions de participation

  • Sexe:

    ALL

  • Âges admissibles:

    12 to 17

Critères de participation

Inclusion Criteria:

* Age 12-17
* Depression and/or anxiety as the primary concern, confirmed by the treating physician
* Intention to start a new SSRI
* English fluency

Exclusion Criteria:

* Co-occurring obsessive compulsive disorder, psychosis, bipolar disorder, eating disorder, autism spectrum disorder, fetal alcohol spectrum disorder, or intellectual disability
* History of non-response to 3 or more SSRI medications as confirmed by the treating physician
* Brain stimulation-based therapy initiated within 8 weeks of referral, or plans to initiate/change brain stimulation during study participation
* History of liver or hematopoietic cell transplant
* History of CYP2B6, CYP2C19, or CYP2D6 testing

Lieu de l'étude

University of Calgary
University of Calgary
Calgary, Alberta
Canada

Contactez l'équipe d'étude

Primary Contact

Laina McAusland, MSc

[email protected]
403-210-6353
Étude parrainée par
University of Calgary
Participants recherchés
Plus d'informations
ID de l'étude: NCT06853587